Contact: Vicki Cohn, (914) 740-2156, email@example.com
Mark Kay Appointed Editor of Human Gene Therapy; Jim Wilson Continues as Editor-in-Chief
New Rochelle, NY, October 23, 2013—Mark A. Kay, MD, PhD, Stanford University School of Medicine, a long-time Associate Editor of Human Gene Therapy, will assume the position of Editor effective immediately. James M. Wilson, MD, PhD, University of Pennsylvania, will continue as Editor-in-Chief of the Human Gene Therapy journal program, including Human Gene Therapy, Human Gene Therapy Methods, and Human Gene Therapy Clinical Development, published by Mary Ann Liebert, Inc., publishers.
"Mark will provide critical leadership in expanding the scope and impact of our flagship journal," says Dr. Wilson, Director of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia.
Dr. Kay is Head of the Division of Human Gene Therapy and the Dennis Farrey Family Professor in the Departments of Pediatrics and Genetics at Stanford University. He received a PhD in Developmental Genetics, and MD from Case Western Reserve in Cleveland, Ohio. Before coming to Stanford in 1998, Dr. Kay was at the University of Washington as Associate Professor in the Departments of Medicine, Biochemistry and Pathology. Dr. Kay was on the founding board of directors of the American Society for Gene Therapy and served as the Society’s Vice-President, President-Elect, and President in 2003-2006. He has served on the Oligonucleotide Therapeutics Board of Directors during the last 5 years. He was elected to the Association of American Physicians in 2010. Dr. Kay received the American Society for Gene and Cell Therapy’s Outstanding Investigator Award in 2013.
Dr. Kay has published over 200 scientific papers. The focus of the laboratory is to establish the scientific principles required for gene and nucleic acid transfer for the treatment of genetic and acquired diseases. Dr. Kay has worked on the development of many DNA transfer vectors and the mechanism by which they transduce tissues in mammals. His group has performed two Phase I/II gene therapy trials for hemophilia B. His laboratory was the first to establish therapeutic RNAi in whole non-embryonic mammals, and RNAi-mediated inhibition of a human viral pathogen (HBV) in animals. His work continues towards defining the molecular limits of delivered and expressed RNAi in vivo as well as the mechanisms involved in si/shRNA-mediated gene silencing and the biological mechanisms involved in miRNA-mediated gene repression. In addition, his laboratory is studying the role that the newly defined small tRNA-derived RNAs play in mammalian gene regulation.
Thierry VandenDriessche, PhD, Head, Division of Gene Therapy & Regenerative Medicine, Faculty of Medicine & Pharmacy, Free University of Brussels (VUB), is Editor of Human Gene Therapy Methods, and Barry J. Byrne, MD, PhD, Powell Gene Therapy Center, University of Florida, College of Medicine, Gainesville, FL, is Editor of Human Gene Therapy Clinical Development. Dr. Wilson remains Editor-in-Chief of all three journals, and Professor George Dickson, Institute of Biomedical & Life Sciences, School of Biological Sciences, University of London, continues as Deputy Editor of the HGT journal program.
About the Journal
Human Gene Therapy, the official journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its sister journal, Human Gene Therapy Methods, published bimonthly, focuses on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development publishes data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of content for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.